Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626925 · ClinicalTrials.gov registry record · Phase 4
Topiramate Treatment of Problem Drinkers
A Phase 4 study, sponsored by UConn Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT00626925 is a Phase 4 study that has completed, run by UConn Health. The registered enrollment target is 200 participants.
The verdict
NCT00626925, a Phase 4 study, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of topiramate in reducing drinking and heavy drinking frequency in problem drinkers. We hypothesize that at a dosage of up to 200mg/day, topiramate will be well tolerated in this patient population and that, compared to placebo treatment, topiramate will result in a greater reduction in the frequency of both drinking days and heavy drinking days.
Interventions
- DRUG placebo
- DRUG topiramate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2008-02 |
| Est. Completion | 2013-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00626925
The ClinicalTrials.gov registry entry for NCT00626925 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00626925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00626925 about?
NCT00626925 is a clinical study titled "Topiramate Treatment of Problem Drinkers". The purpose of this study is to evaluate the safety and efficacy of topiramate in reducing drinking and heavy drinking frequency in problem drinkers. We hypothesize that at a dosage of up to 200mg/day, topiramate will be well tolerated in this patient population and that, compared to placebo treatme...
What is the current status of trial NCT00626925?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2008-02. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00626925?
The interventions under investigation include: placebo (DRUG), topiramate (DRUG).
Who is sponsoring clinical trial NCT00626925?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.